

Abattis Announces the Appointment of New Independent Director

Vancouver, BC – November 2, 2016 - Abattis Bioceuticals Corp. (the "**Company**" or "**Abattis**") (OTCQB: ATTBF) (CSE: ATT), announces the appointment of Dr. William Panenka to the Board of Directors.

Dr. Panenka received his M.D. and M.Sc. from the University of Calgary in Canada. His M.Sc. was basic science-focused utilizing Western Blotting, PCR, in-situ hybridization and other wet lab techniques. He completed residencies in both psychiatry and neurology at the University of British Columbia in Vancouver, Canada.

In 2011 Dr. Panenka began a research fellowship focusing on the mental and physical health, as well as the brain imaging correlates of drug use and addictions. In 2012, he became a research fellow at Harvard University and was competitively recruited to the University of British Columbia in 2013 as an assistant professor in psychiatry. His main focus is addiction and traumatic brain injury, with multiple basic science and clinical collaborations nationally and internationally.

Dr. Panenka is currently a co-investigator on several clinical studies involving Cannabis, focusing on the effects of THC and CBD on psychosis, mood and anxiety. In collaboration with a local biotech start-up company, his team at UBC was recently awarded a MITACS industry-academic partnership grant to partially fund this research.

According to Rene David, CFO and acting CEO of Abattis Bioceuticals, "We are extremely pleased Dr. Panenka has agreed to join our board as an independent director. He provides us with a wealth of knowledge and experience as a clinician, researcher and professor and welcome his input with respect to our nutraceutical product lines and controlled substances testing facility. We look forward to his guidance as Abattis and subsidiaries navigate the legal cannabis industry."

About Abattis Bioceuticals Corp.

Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

About Northern Vine Canada Inc.

Northern Vine Labs™ is licensed by Health Canada for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurance programs incorporate global best practices and procedures for application in the Canadian market.

About Vergence Visionary Bioceuticals Corp.

Vergence Visionary Bioceuticals, dba Vergence Sales and Marketing Group, is a wholly owned subsidiary of Abattis Bioceuticals Corp. based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast growing market for natural, safe and effective natural products that meet unmet wellness needs.

ON BEHALF OF THE BOARD

"Rene David"

Rene David, CFO, Acting CEO

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time. **NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.**